Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LHCGR | P22888 | 9/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HHAT | Q5VTY9 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2309732 | 0.92 | LHCGR (0.51) | LHCGRMAPK1NPSR1 | |
| SCHEMBL2307641 | 0.92 | LHCGR (0.51) | LHCGRHHAT | |
| SCHEMBL2306792 | 0.85 | LHCGR (0.55) | LHCGRHHAT | |
| SCHEMBL2307807 | 0.85 | TAAR1 (0.51) | LHCGRMAPK1NPSR1HHAT | |
| SCHEMBL2310036 | 0.85 | LHCGR (0.53) | LHCGRMAPK1NPSR1 | |
| SCHEMBL2306483 | 0.85 | LHCGR (0.57) | LHCGRMAPK1NPSR1HHAT | |
| SCHEMBL2312192 | 0.84 | LHCGR (0.52) | LHCGRMAPK1NPSR1 | |
| SCHEMBL2308391 | 0.83 | HHAT (0.56) | LHCGRMAPK1NPSR1HHAT | |
| SCHEMBL2310191 | 0.83 | HHAT (0.54) | LHCGRHHAT | |
| SCHEMBL2306671 | 0.81 | HHAT (0.53) | LHCGRHHAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350093-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDROTHIENOPYRIDINES AS KCNQ2/3 MODULATORS FOR TREATING PAIN, EPILEPSY AND URINARY INCONTINENCE | GRUENENTHAL GMBH (DE) | 2012-10-03 | — | — | EP | claimed |
| EP-2350093-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROTHIENOPYRIDINES AS KCNQ2/3 MODULATORS FOR TREATING PAIN, EPILEPSY AND URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2011-08-03 | — | — | EP | claimed |
| WO-2010046108-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROTHIENOPYRIDINES AS KCNQ2/3 MODULATORS FOR TREATING PAIN, EPILEPSY AND URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2010-04-29 | — | — | WO | claimed |
| US-20100105722-A1 | Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators | GRUENENTHAL GMBH (DE) | 2010-04-29 | — | — | US | claimed |
| EP-2350093-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDROTHIENOPYRIDINES AS KCNQ2/3 MODULATORS FOR TREATING PAIN, EPILEPSY AND URINARY INCONTINENCE | GRUENENTHAL GMBH (DE) | 2012-10-03 | — | — | EP | disclosed |
| EP-2350093-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROTHIENOPYRIDINES AS KCNQ2/3 MODULATORS FOR TREATING PAIN, EPILEPSY AND URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010046108-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROTHIENOPYRIDINES AS KCNQ2/3 MODULATORS FOR TREATING PAIN, EPILEPSY AND URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2010-04-29 | — | — | WO | disclosed |
| US-20100105722-A1 | Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators | GRUENENTHAL GMBH (DE) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105722-A1 | Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators | KCNQ1, KCNQ3, KCNQ2 | LHCGR 3809/4885MAPK1 1262/4885NPSR1 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.